Risk assessment of biocide and antibiotic resistance Workshop

"What concerns me is not the way things are, but rather the way people think things are."



Keith Baptiste



A timely reality check on silent pandemic of antimicrobial resistance

New evidence shows that, in 2019, AMR was the direct cause of at least 1.27 million global deaths. This number is only set to grow further, unless action is taken.



Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

THE LANCET

<u>Volume 399, ISSUE 10325</u>, P629-655, February 12, 2022. DOI:<u>https://doi.org/10.1016/S0140-6736(21)02724-0</u>



Antimicrobial consumption and resistance in bacteria from humans and animals

Third joint inter-agency report on integrated analysis of antimicrobial agent consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the EU/EEA

> JIACRA III 2016–2018

Figure III: Population-weighted mean of the total consumption of antimicrobials in humans^(a) and food-producing animals^(b) in 27 EU/EEA countries^(c) for which data were available for both humans and food-producing animals, for 2014–2018





Fundamental differences in Antimicrobial use between Veterinary & Human Medicine

Off-labe

High use in healthy animals (e.g. prophylaxis/metaphylaxis)

Many EU member states are allow veterinarians to make profit from the sales/prescription of medicines

High percentage of off-label usage

"The use of a veterinary medicinal product that is not in accordance with the summary of the product characteristics (SPC), including the misuse and serious abuse of the product." European Directive 2001/82/EC (Official Journal L -311, 28/11/2004, p. 1 – 66)



European overall sales=5577.8 tonnes of antimicrobials: 86.9% of sales were VMPs either for bulk animal feed or drinking water.



Antimicrobial Premixes, oral powders/granules for bulk animal feed

Figure 8. Distribution of sales, in mg/PCU, of the various product forms of antimicrobial VMPs for food-producing animals, aggregated by the 31 European countries, in 2020



Premix

- Oral powder
- Oral solution
- Injectable products
- Intramammary products
- Other forms*

 * `Other forms' includes oral pastes, boluses and intrauterine products.

TapAntimicrobial Powders/granules, oral solutions for
common drinking water

Sales of veterinary

in 31 European countries in 2019

Treads from 2010 to 2020

the second in the same second

and 2020

antimicrobial agents

"It ain't what you don't know that gets you into trouble. It's what you know for sure that just ain't so." Mark Twain (1835 – 1910)

Highlights of the NVR on antimicrobials in VMPs & MF

Mass medication bans

- > Ban on preventative use of antibiotics in groups of animals.
- > Ban on preventative use of antibiotics via medicated feed.
- **> Re-inforced ban on antibiotics for growth promotion**(including third country trading partners).

Restrictions

- > Restrictions on antibiotics for metaphylaxis
- > List of antibiotics for human-use only (ban in veterinary medicine)
- Restrictions of specific antimicrobials under 'Cascade-use' (off-label)
 Data collection
- > Compulsory data collection (EU wide) on sales & use of antimicrobials (animal species level)





Changes in CVMP Antimicrobial Veterinary Assessments

Preliminary Risk Profile



- The purpose is to consider the AMR risk to public health from a NEW substance or VMP
- Identify potential need for risk management measures.
- The intended benefit is to provide early stage feedback to applicants and thereby encourage the pharmaceutical industry to develop new antimicrobials for animals.
- Applicants must pay for the assessment.

Risk Assessment Guideline for Food Animals

- Legally required for applications under Article 8(2), Article 19 (hybrids), Article 62 (variations requiring assessment)
- Used in Referrals addressing concerns over the AMR risk to human health
- The GL does not apply to Article 18 generics.





TERRESTRIAL ANIMAL HEALTH CODE

- Not specifically developed for AMR
- Easily adaptable
- Relatively simple to understand
- Less frequently updated
- Lacks detail/transparency for complex risk assessments
- Assumptions needed for risk estimate



Food and Agriculture Organization of the United Nations



CODEX ALIMENTARIUS

- Specifically developed for AMR
- Not easily adaptable
- Requires training to understand
- Frequently updated
- Very detailed/transparent for complex risk assessments
- > No assumptions needed for risk estimate

8

Scope of the CVMP Risk Assessment Guideline

- The risk question addresses:
 - Risk to human health e.g. loss of treatment options, burden on healthcare services, mortalities (not animal health or the environment)
 - Use of an antimicrobial VMP in line with the intended SPC (target species, formulation, dosing regimen) (not off-label use)
- Food-producing species (not companion animals)
- AMR transfer via food and direct contact (not environment)
- Risk assessment only (not risk management, communication)



Hazard identification

Identification of AMR bacteria or AMR genes (ARG) therein that are selected by use of the antibiotic in target animal species and may be associated with human illness

Release assessment

Probability that resistant bacteria/ARG are selected in the animal following use of the VMP under its proposed conditions, up to 'release' at the time of slaughter, collection of food produce or via direct animal contact

Exposure assessment

Amount of human exposure to the hazard (resistant bacteria/ARG) through food consumption or direct contact and probability of its occurring

Consequence assessment

The potential adverse health effects in humans after exposure to the hazards (resistant bacteria/ARG), their severity and probability of occurring

Risk estimate

Overall estimation of the AMR risk to public health from the use of the antimicrobial VMP according to its conditions of use



Thoughts on Regulatory Antimicrobial Risk Assessments

> Not fully implemented. Not much experience at this stage.

- > Unclear how risks assessments can be objectively evaluated.
 - Biased from the start (based on WHO classification)
 - > EU commission also wish to promote availability of VMPs
- Impact of a newly authorised veterinary antimicrobial, that has been through the risk assessment process, will not likely affect population-level antimicrobial resistance for years after authorisation.

> Not designed to take into account the impact of off-label usage

- > Not designed to take into account the impact on the environment
- > Only designed for food animals (not all species) and not companion animals.

OPEAN MEDICINES AGENCY

MEDICINES HEALTH

Følg os



